|By PR Newswire||
|February 14, 2014 05:15 PM EST||
BEDFORD, Ohio, Feb. 14, 2014 /PRNewswire/ -- Ben Venue Laboratories, Inc. today issued a nationwide voluntary product recall:
Acetylcysteine Solution 10%, USP, (Manufactured for Roxane Laboratories, Inc.)
10%, 30 mL per vial – NDC #0054-3025-02 – Lot 2005479 – Exp. Date March 2014
This voluntary recall was initiated on February 14, 2014 after the discovery of a single visible glass particle in a vial within the lot listed above. There have been no complaints or adverse events related to a piece of glass in vials of this lot. All other product parameters were within specifications.
Acetylcysteine for inhalation is usually delivered via a Nebulizer, but can also be delivered via direct instillation into a tracheostomy, or into the bronchial-pulmonary tree during bronchoscopy. Glass particles can cause airway obstruction resulting in symptoms of choking, wheezing, difficulty breathing, coughing and potentially hemoptysis. Use of an inhaled product with glass particles has the potential to cause choking which could be life-threatening. Aerosolization of small glass particles in the airways could result in recurrent infections (due to obstruction of airways, and decreased clearance of airway secretions).
Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretion. Acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen.
The nationwide voluntary recall is to the patient level. This recall is limited to the one lot number listed above.
Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers should not use the product lot listed above for patient care and should immediately quarantine any product for return.
Patients who may have received product dispensed from this one lot should return the product to their pharmacist. Distributors/retailers that have not received a recall packet should contact GENCO Pharmaceutical Services, 6101 North 64th Street, Milwaukee, WI 53218.
For information regarding the recall process, call GENCO at 800-633-1422. For technical product information or to report a technical product complaint, call 800-962-8364 and select menu option 5.
Adverse reactions or quality problems experienced with the use of this product may be reported to the U.S. Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Ben Venue Laboratories has informed the FDA of its actions and is maintaining ongoing discussion with the agency. This nationwide voluntary recall is being conducted with the knowledge of the FDA.
Ben Venue is located in Bedford, Ohio. For more information, visit www.benvenue.com.
SOURCE Ben Venue Laboratories, Inc.
Apr. 23, 2017 01:15 PM EDT Reads: 4,647
Apr. 23, 2017 01:00 PM EDT Reads: 3,141
Apr. 23, 2017 01:00 PM EDT Reads: 1,881
Apr. 23, 2017 12:45 PM EDT Reads: 1,241
Apr. 23, 2017 11:45 AM EDT Reads: 2,165
Apr. 23, 2017 11:30 AM EDT Reads: 2,388
Apr. 23, 2017 11:15 AM EDT Reads: 608
Apr. 23, 2017 10:15 AM EDT Reads: 485
Apr. 23, 2017 09:45 AM EDT Reads: 1,792
Apr. 23, 2017 09:15 AM EDT Reads: 805
Apr. 23, 2017 08:15 AM EDT Reads: 3,667
Apr. 23, 2017 07:45 AM EDT Reads: 1,812
Apr. 23, 2017 07:15 AM EDT Reads: 1,455
Apr. 23, 2017 07:00 AM EDT Reads: 1,508
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Apr. 23, 2017 04:45 AM EDT Reads: 2,759